Sumatriptan: update and review

Authors: Cady, Roger¹; Schreiber, Curtis²

Source: Expert Opinion on Pharmacotherapy, Volume 7, Number 11, August 2006 , pp. 1503-1514(12)

Buy & download fulltext article:

Price: $99.00 plus tax (Refund Policy)

Abstract:

Sumatriptan is the first of a novel class of medications referred to as triptans. Since its approval for migraine in the 1990s, six other triptan products have received FDA approval. Despite the proliferation of triptans, sumatriptan remains the most frequently prescribed product in this therapeutic class. Sumatriptan has been instrumental in defining a biological basis for migraine. It is effective in treating migraine with or without aura, well tolerated and, when properly prescribed, safe. Sumatriptan injection is the only member of the triptan class approved for treatment of cluster headache. Studies with sumatriptan have also advanced the therapeutic intervention paradigm that permits patients to treat earlier and avoid substantial disability. Numerous pharmacoeconomic studies have demonstrated that sumatriptan decreases work loss productivity and improves quality of life.

Keywords: migraine; sumatriptan; triptans

Document Type: Drug Evaluation

DOI: http://dx.doi.org/10.1517/14656566.7.11.1503

Affiliations: 1: 1Director, Headache Care Center, 3805 S. Kansas Expressway, Springfield, MO 65804, USA 2: 2Associate Director, Headache Care Center, 3805 S. Kansas Expressway, Springfield, MO 65804, USA

Publication date: 2006-08-01

More about this publication?